Cantargia Presents Association Between Nadunolimab and Reduction of Chemotherapy Induced Peripheral Neuropathy (CIPN) at AACR

LUND, SE / ACCESS Newswire / April 25, 2025 / Cantargia (STO:CANTA)

• Clinical findings show association between nadunolimab and lower incidence and later onset of CIPN

Preclinical data show prevention of both chemotherapy- and antibody-drug conjugate- (ADC) payload-induced neuropathy by a nadunolimab surrogate, supporting the clinical observations and suggesting an extension of benefits into the ADC field

Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today released a poster on nadunolimab's potential in reducing the treatment-limiting burden of CIPN in metastatic cancer patients. Findings from the CANFOUR trial demonstrated that any-grade CIPN was less frequent in patients receiving higher doses of nadunolimab, compared to patients in the lower dose group. This is now supported by data from patients in two additional clinical trials as well as data from several preclinical models. Together the data suggests that nadunolimab may combine antitumor activity with a potent reduction of CIPN.

"The data that is presented at AACR show an association of nadunolimab with both a lower incidence and a delayed onset of CIPN caused by nab-paclitaxel or oxaliplatin. Given the persistent and often treatment-limiting nature of CIPN, any reduction in its severity or occurrence could represent a very meaningful clinical advantage. It is also very encouraging to see that a murine surrogate to nadunolimab can reduce not only CIPN induced by several different chemotherapy drugs, but also neuropathy induced by ADC payloads" said David Liberg, Chief Scientific Officer at Cantargia.

Peripheral neuropathic pain, a common and often severe side effect, can be triggered by both chemotherapy and ADCs through inflammatory pathways. This type of pain can profoundly impact a patient's quality of life, sometimes necessitating dose reductions or even discontinuation of treatment.

Nadunolimab shows promising clinical benefit in combination with standard of care chemotherapies. The CANFOUR trial in advanced pancreatic cancer (PDAC) where nadunolimab was combined with nab-paclitaxel and gemcitabine, showed an impressive 48% ORR, 14.2 months OS, and 35% 24 months survival in patients with high levels of IL1RAP protein expression in tumor cells. Additionally, a potential neuroprotective role of nadunolimab was observed in the same trial, which could provide patients with dual benefits of tumor control and reduced treatment-related neuropathy.